Arrow-right Camera
Go to e-Edition Sign up for newsletters Customer service
Subscribe now


News >  Nation/World

FDA approves updated coronavirus shots for young children

Dec. 9, 2022 Updated Fri., Dec. 9, 2022 at 9:11 p.m.

Physician Sarah Schaffer Deroo calms her 7 month-old-son, Hewitt, as he receives a coronavirus vaccine in D.C. MUST CREDIT: Washington Post photo by Bill O'Leary.  (Bill O'Leary/The Washington Post)
Physician Sarah Schaffer Deroo calms her 7 month-old-son, Hewitt, as he receives a coronavirus vaccine in D.C. MUST CREDIT: Washington Post photo by Bill O'Leary. (Bill O'Leary/The Washington Post)
By Laurie McGinley Washington Post

Federal regulators Thursday authorized an updated booster shot of Moderna’s coronavirus vaccine for young children, saying the immunization would offer increased protection amid a wave of respiratory illnesses that is increasing peril for youngsters. This means the youngest Americans will have access to variant-targeting boosters already available to older children and adults.

The Food and Drug Administration, in a statement, said children 6 months through 5 years old would be eligible for the booster – known as a “bivalent” shot targeting the omicron subvariants BA.4 and BA.5 and the original version of the virus – two months after they had completed Moderna’s two-dose primary series.

The agency also cleared an updated shot of the coronavirus vaccine by Pfizer and its German partner BioNTech for children 6 months through 4 years old. That bivalent shot, which also targets omicron, will be substituted for the last shot in the companies’ initial three-dose series. It is not considered a booster shot.

The FDA in June authorized a two-shot series of the Moderna vaccine of 25 micrograms each for young children, and a three-dose regimen of the Pfizer-BioNTech vaccine of 3 micrograms each. Pfizer and BioNTech have said they chose a lower dose to minimize potential side effects.

The Centers for Disease Control and Prevention on Friday endorsed the FDA’s latest action, saying in a statement that it has “expanded the use of updated (bivalent) COVID-19 vaccines for children ages 6 months through 5 years.” Children ages 6 months through 5 years who previously completed a Moderna primary series are now eligible to receive a Moderna bivalent booster two months after their final primary series dose. Children ages 6 months through 4 years who are completing a Pfizer primary series will receive a Pfizer bivalent vaccine as their third primary dose.

The updated vaccines are formulated to protect against some of the more recently circulating subvariants and are “critical to providing ongoing protection as immunity wanes and the virus continues to mutate,” the CDC said. “The vast majority of children in this age group have not received any doses of a COVID-19 vaccine.”

CDC said it is working to increase parent and provider confidence in the coronavirus vaccines to improve uptake among the 95% of children who are not vaccinated or who have not completed the vaccine primary series.

The government’s latest effort to bolster protections is bumping up against an unwelcome fact: Only a small percentage of young children have been vaccinated against the coronavirus. Fewer than 5% of children 4 and younger have completed an initial series of a coronavirus vaccine, and fewer than 10% have received even a first shot, according to the CDC.

Federal health officials, eyeing a rise in COVID-19 cases and pediatric hospitalizations because of an array of respiratory germs, said it was important to make updated shots available to the youngest age groups.

Peter Marks, the FDA’s top vaccine regulator, said the agency wanted “parents who are trying to optimally protect their children” to have access to the most-up-to-date versions of the vaccine. He also said the authorizations give the agency another opportunity to stress that all children should be vaccinated against the coronavirus because it is the best way to prevent the worst outcomes, including hospitalization and death.

With temperatures dropping and activities moving indoors, the nation is “entering into another wave of COVID,” Marks said. “We don’t know how high it is going to go.”

The BA.4 and BA.5 coronavirus subvariants, which were circulating widely this summer, have faded and are responsible for below 15% of cases, according to the CDC.

They have been replaced by BQ.1 or BQ.1.1, which are causing more than 60% of cases in the United States.

Officials say the bivalent formulation will offer improved protection against the latest crop of omicron subvariants. Still, that shield is not foolproof: The latest mutants have proved adept at dodging some of the protective antibodies generated by even that shot.

Some vaccine experts are worried that the emergency authorizations could cause confusion among parents, especially those whose children have received the Pfizer-BioNTech vaccine. The bottom line is this: Children who have not started getting that vaccine’s three-dose series, or have received only two shots, will get the bivalent vaccine, not the original shot, as their third immunization.

But children who have received the three-shot primary series of the Pfizer-BioNTech vaccine will not be eligible immediately for a booster. The FDA is expected to review data for a bivalent booster for the Pfizer-BioNTech shots early next year. These children “would still be expected to have protection against the most serious outcomes from the currently circulating omicron variant,” the FDA said.

Children’s hospitals in the United States are under strain as they care for unusually high numbers of children infected with RSV and other respiratory viruses. Doctors worry that the numbers will rise as families and friends gather for the holidays.

But the boosters have hardly been embraced, even by adults. The uptake of a bivalent booster has been lackluster, and the White House recently said it would launch a six-week push to increase booster rates among older people, in communities of color and in rural areas – all of which have suffered disproportionately high rates of severe disease and death during the coronavirus pandemic.

The Spokesman-Review Newspaper

Local journalism is essential.

Give directly to The Spokesman-Review's Northwest Passages community forums series -- which helps to offset the costs of several reporter and editor positions at the newspaper -- by using the easy options below. Gifts processed in this system are not tax deductible, but are predominately used to help meet the local financial requirements needed to receive national matching-grant funds.

Active Person

Subscribe now to get breaking news alerts in your email inbox

Get breaking news delivered to your inbox as it happens.